New Study on Classic CAH Treatment and Management
FDA Approves First New Treatment for Classic Adrenal Disorder in 70 Years
First New Drug for Rare Hormonal Disorder in 70 Years Approved
Biopharma Company Discontinues Drug Trials Following Efficiency Changes
Anastrozole Boosts Height in Children with Adrenal Disorder
New treatment enhances child growth and Genetic screening for newborns
Treatment breakthroughs, case studies, and diagnostic challenges.
Empowering CAH patients: tailored diet, enhanced bone health, and support for lifelong symptom management.
Advocacy for emergency school training; support for intersex health research; biopharmaceutical innovation for rare conditions.
The impact of CAH on quality of life, the establishment of neonatal steroid hormone reference intervals for early diagnosis of CAH and related disorders, and women's perspectives on the timing of genital surgery in CAH
